Table 1 Demographic, clinical, and biochemical data of IgAN patients
From: Poor histological lesions in IgA nephropathy may be reflected in blood and urine peptide profiling
IgAN patients | ||
|---|---|---|
At the time of initial biopsy | At the end of follow-up | |
Number of patients | 19 | |
Age, years | 42 (33–52) | 44 (35–54) |
Gender (Male), n (%) | 15 (79) | |
Hypertension (Yes), n (%) | 12 (63) | |
Diabetes (Yes), n (%) | 1 (5) | |
Dyslipidemia (Yes), n (%) | 9 (47) | |
Serum creatinine, mg/dl | 2.00 (1.40-2.57) | 3.16a (1.26-6.18) |
Uric acid, mg/dl | 7.40 (5.45-8.30) | 7.40 (6.55-9.20) |
Serum albumin, g/l | 34.00 (31.00–39.00) | 40.00a (36.75–42.40) |
Cholesterol, mg/dl | 194.00 (157.00–221.75) | 147.00a (131.50-213.00) |
Proteinuria, g/24 hours | 2.28 (1.20-4.26) | 1.30 (0.52-3.27) |
RAAS blockade (Yes), n (%) | 7 (37) | 17 (89) |
ACEI | 5 (26) | 11(58) |
ARB | 1 (5) | 3(16) |
ACEI plus ARB | 1 (5) | 3(16) |
Statins (Yes), n (%) | 4 (21) | 9 (47) |